Search Results

Duchesnay Inc., member of Duchesnay Pharmaceutical Group (DPG) one of the few anchor companies selected by the Government of Canada for its Global Hypergrowth Project, has recently filed a New Drug Submission (NDS) to Health Canada for its segesterone acetate / ethinyl estradiol slow-release vaginal system developed for contraception control.

Duchesnay Inc, a pharmaceutical company specializing in women’s health and part of Duchesnay Pharmaceutical Group headquartered in Blainville, Quebec, is pleased to announce that it has launched its newest treatment, Vablys ® (dequalinium chloride vaginal tablets).

◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.

A new progestin-only contraceptive pill is now available to Canadians from Duchesnay Inc., a pharmaceutical company specializing in women’s health and part of the Duchesnay Pharmaceutical Group headquartered in Blainville, Quebec.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Duchesnay Inc., a pharmaceutical company specializing in women’s health and part of the Duchesnay Pharmaceutical Group based in Blainville, Quebec, is proud to announce the first treatment launched by its new ownership and management team to help postmenopausal women across Canada who are suffering from vaginal dryness and painful intercourse.

Duchesnay Inc. is pleased to announce that Slynd®, used to prevent pregnancy in girls and adult women aged 12 years and older who can become pregnant, is now listed for public reimbursement on the Public Prescription Drug Insurance Plan of the Régie de l’assurance maladie du Québec.